2G7-24926-66385
3 vaccinations
1 coded response
38 check-ins
0 free-text entries
0 call cases
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 910 / CA
- Registered
- 2021-02-01
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-01
Registered in v-safe
-
2021-02-01
Dose 1 — Pfizer-BioNTech
- 2021-02-01
- 2021-02-03
- 2021-02-04
- 2021-02-05
- 2021-02-06
- 2021-02-07
- 2021-02-08
- 2021-02-15
-
2021-02-22
Dose 2 — Pfizer-BioNTech
-
2021-02-22
Health check-in — day 0, dose 2Feeling: Good · Site: Pain · Muscle or body aches, NauseaAdult check-in
- 2021-02-23
- 2021-02-24
- 2021-02-25
- 2021-02-26
- 2021-02-27
- 2021-02-28
- 2021-03-01
- 2021-03-08
- 2021-03-15
- 2021-03-22
- 2021-03-29
- 2021-04-05
- 2021-05-24
- 2021-08-23
-
2022-01-14
Dose 3 — Pfizer-BioNTech
-
2022-01-15
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2022-01-16
-
2022-01-17
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2022-01-18
-
2022-01-19
Health check-in — days 1–6 daily, dose 3Feeling: Good · Muscle or body aches, Fatigue or tirednessAdult check-in
-
2022-01-20
Health check-in — days 1–6 daily, dose 3Feeling: Good · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2022-01-21
- 2022-01-28
- 2022-02-04
- 2022-02-11
- 2022-02-18
- 2022-02-25
- 2022-04-15
- 2022-07-15
-
2023-01-14
Survey response — 12 months, dose 3MedDRA: COVID-19, Chills, Cough, Fatigue, Headache, Oropharyngeal pain, Pain, Pyrexia, Respiratory tract congestion, Rhinorrhoea — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activitiesMedDRA releases: 2024-11
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-01 | Pfizer-BioNTech | |
| 2 | 2021-02-22 | Pfizer-BioNTech | |
| 3 | 2022-01-14 | Pfizer-BioNTech | No |
Free text
None.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chills | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release